Polaryx Therapeutics PLYX
NASDAQ PLYX
$2.08 +0.06 (+2.97%)
At close: Oct 2, 2026 · 4:00 PM EDT

Polaryx Therapeutics (PLYX) Return on Assets [ROA] (2026)

Updated

Polaryx Therapeutics (PLYX) recorded Return on Assets [ROA] of -121.12% in Q2 2026.

Analysis

Polaryx Therapeutics (PLYX) Return on Assets [ROA] (2026) Analysis & Trends

For FY2025, Polaryx Therapeutics reported Return on Assets [ROA] of -153.79%.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROA (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn 20.64%
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn 10.47%
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn 4.65%
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn 2.45%
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn 28.37%
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn 9.10%
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn 9.29%
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn -6.13%
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn 2.14%
10 Polaryx Therapeutics 100.69 Mn 76.30 Mn - -121.12%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -121.12%
API Access

Polaryx Therapeutics Return on Assets [ROA] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-assets-%5Broa%5D&ticker=PLYX&period=max&api_key=YOUR_API_KEY